RESUMEN
Forty-three patients with a recently healed duodenal ulcer were entered into a 1-year double-blind trial to evaluate the efficacy and tolerance of ranitidine (Zantac; Glaxo). There were no drop-outs. After 1 year 18 of the 22 patients receiving 150 mg ranitidine at night (82%) and 3 of the 21 receiving placebo (14%) were ulcer- and symptom-free. No drug-related side-effects were noticed. A maintenance dose of ranitidine seems to be a safe and effective means of preventing duodenal ulcer recurrence.
Asunto(s)
Úlcera Duodenal/prevención & control , Ranitidina/uso terapéutico , Adulto , Ensayos Clínicos como Asunto , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Distribución Aleatoria , RecurrenciaRESUMEN
Ultrastructural studies were conducted on biopsy specimens taken by endoscopy from the edge of gastric ulcers in the distal part of the stomach of 9 patients before and after treatment with either bicitropeptide or cimetidine. Marked depletion of mucin granules in the mucous epithelial cells and the pyloric gland cells was found in all patients and there was morphological evidence of a block in the synthesis of mucus glycoproteins. This block was located in the Golgi region of these cells. Synthesis of structurally normal mucin granules was restored after treatment with either bicitropeptide or cimetidine.
Asunto(s)
Antiulcerosos/farmacología , Bismuto/farmacología , Cimetidina/farmacología , Guanidinas/farmacología , Metaloproteínas , Proteínas/farmacología , Úlcera Gástrica/patología , Adulto , Antiulcerosos/uso terapéutico , Cimetidina/uso terapéutico , Femenino , Humanos , Masculino , Microscopía Electrónica , Persona de Mediana Edad , Úlcera Gástrica/tratamiento farmacológico , Factores de TiempoRESUMEN
A bismuth-peptide complex (BCP Compound), an antacid (Maalox) and corresponding placebos were studied in a 6-week comparative double-blind trial of treatment in 106 randomized ambulant patients with endoscopically proven duodenal and gastric ulcers. Patients were examined after 1, 3 and 6 weeks' treatment and results assessed separately for duodenal and gastric ulcers on endoscopic evidence at weeks 3 and 6 respectively. Bicitropeptide was significantly better than antacid and placebo at 3 and 6 weeks for treatment of both duodenal and gastric ulcers. In the bicitropeptide group 100% of the patients in the duodenal ulcer group and 95,2% in the gastric ulcer group responded to treatment (improved or healed). No haematological or biochemical changes were noted and no adverse effects were recorded.
Asunto(s)
Antiácidos/uso terapéutico , Bismuto/uso terapéutico , Úlcera Duodenal/tratamiento farmacológico , Proteínas/uso terapéutico , Adulto , Ensayos Clínicos como Asunto , Método Doble Ciego , Evaluación de Medicamentos , Femenino , Humanos , Masculino , Úlcera Péptica/tratamiento farmacológico , PlacebosRESUMEN
Forty-seven patients were treated in a double-blind trial to evaluate the efficacy of 400 mg cimetidine, an H2- receptor antagonist (Tagamet; SKF), twice a day in the prevention of recurrent duodenal ulcers. A total of 7 patients was not considered in the final evaluation; 6 patients withdrew, while 1 patient did not maintain the prescribed treatment. Of the remaining 40 patients, 26 took cimetidine and 14 placebo. Ulcers recurred in all placebo patients within a year. Of the cimetidine patients, 2 had recurrent ulcers within a year, while 3 more had other endoscopic abnormalities at the termination of treatment. The remaining 21 patients (80,8%) had no abnormalities which could be endoscopically observed at the end of a year. It may be concluded that a maintenance dose of cimetidine significantly reduces the risk of recurrence of a duodenal ulcer.
